FMP
Zosano Pharma Corporation
ZSAN
NASDAQ
Inactive Equity
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
0.558 USD
0 (0%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
443.89M
485.69M
557.42M
623.94M
724.14M
818.6M
925.38M
1.05B
1.18B
1.34B
Revenue %
-
9.42
14.77
11.93
16.06
13.04
13.04
13.04
13.04
Ebitda
141.94M
228.44M
259.48M
292.14M
-
282.22M
319.04M
360.65M
407.7M
460.88M
Ebitda %
31.98
47.03
46.55
46.82
-
34.48
34.48
34.48
34.48
Ebit
123.51M
208.4M
237.43M
269.95M
-21.68M
251.47M
284.27M
321.36M
363.28M
410.66M
Ebit %
27.82
42.91
42.59
43.27
-2.99
30.72
30.72
30.72
30.72
Depreciation
18.42M
20.04M
22.05M
22.19M
21.68M
30.75M
34.76M
39.3M
44.42M
50.22M
Depreciation %
4.15
4.13
3.96
3.56
2.99
3.76
3.76
3.76
3.76
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
